Investors sold shares of ABIOMED, Inc. (NASDAQ:ABMD) on strength during trading hours on Friday. $47.25 million flowed into the stock on the tick-up and $367.84 million flowed out of the stock on the tick-down, for a money net flow of $320.59 million out of the stock. Of all companies tracked, ABIOMED had the 0th highest net out-flow for the day. ABIOMED traded up $2.90 for the day and closed at $384.88

Several brokerages have recently issued reports on ABMD. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. ValuEngine cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. Piper Jaffray Companies increased their price target on shares of ABIOMED from $360.00 to $480.00 and gave the stock an “overweight” rating in a research report on Friday, June 22nd. Finally, Jefferies Financial Group increased their price target on shares of ABIOMED to $460.00 and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. ABIOMED has a consensus rating of “Buy” and an average target price of $374.88.

The company has a market capitalization of $17.27 billion, a price-to-earnings ratio of 157.09, a P/E/G ratio of 4.11 and a beta of -0.07.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.80 by $1.15. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The firm had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. During the same period in the prior year, the firm earned $0.82 earnings per share. The business’s quarterly revenue was up 35.9% compared to the same quarter last year. equities analysts forecast that ABIOMED, Inc. will post 3.46 earnings per share for the current fiscal year.

In related news, VP Andrew J. Greenfield sold 4,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total transaction of $1,753,800.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO David M. Weber sold 19,282 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $356.77, for a total transaction of $6,879,239.14. Following the sale, the chief operating officer now owns 167,124 shares in the company, valued at $59,624,829.48. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in ABMD. BlackRock Inc. increased its stake in ABIOMED by 4.9% in the first quarter. BlackRock Inc. now owns 3,697,535 shares of the medical equipment provider’s stock valued at $1,075,946,000 after purchasing an additional 172,329 shares during the last quarter. Baillie Gifford & Co. increased its stake in ABIOMED by 3.0% in the second quarter. Baillie Gifford & Co. now owns 2,106,320 shares of the medical equipment provider’s stock valued at $861,591,000 after purchasing an additional 61,385 shares during the last quarter. Renaissance Technologies LLC increased its stake in ABIOMED by 35.0% in the second quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock valued at $634,610,000 after purchasing an additional 401,800 shares during the last quarter. Winslow Capital Management LLC purchased a new position in ABIOMED in the first quarter valued at approximately $228,454,000. Finally, FMR LLC increased its stake in ABIOMED by 34.2% in the second quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock valued at $282,988,000 after purchasing an additional 176,394 shares during the last quarter. Hedge funds and other institutional investors own 86.21% of the company’s stock.

ABIOMED Company Profile (NASDAQ:ABMD)

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.